CSC Adds Two Industry Leaders in Luxembourg; Secures Fund Administration and Depositary Licenses for Additional Services
21.9.2021 11:00:00 EEST | Business Wire | Press release
CSC, the world’s leading provider of business, legal, tax, and digital brand services, has significantly expanded its operations in Luxembourg by securing new fund administration and depositary licenses and adding two experienced executives to help lead its growth in the market. This further extends CSC’s European fund administration and depositary offerings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005284/en/
Yves Cheret (Photo: Business Wire)
With these key hires, clients will benefit from the addition of more than 30 years of combined industry expertise to CSC’s long-standing service offerings, including a range of alternative investment, capital markets, and corporate solutions. In addition, these new licenses will open new and essential services to clients in Luxembourg, yet another key European financial center in CSC’s growing footprint.
Veteran talent, local expertise
Pierre Mifsud joins as managing director for depositary services for CSC Global Financial Markets (GFM), while Yves Cheret comes aboard as managing director of fund administration for CSC GFM. Both will work with Laurent Bélik, managing director of Capital Markets Europe, who is responsible for general management, including finance and operations in Luxembourg.
“Pierre and Yves will add tremendous value for our clients,” said Bélik. “Because CSC is privately owned, we can invest additional time and effort to build long-term relationships with our clients and focus on the complexities of their unique needs and markets. We take the same approach with our employees, which has allowed us to develop and retain top industry talent to provide clients with the knowledge base, stability, and world-class service that CSC is known for, both locally and around the world.”
Mifsud comes to CSC with more than 15 years of experience in the alternative funds industry, with a focus on private equity, real estate, venture capital, infrastructure, and debt funds. Mifsud previously held leadership roles at Edmond de Rothschild (Europe) S.A., Citco Bank Nederland N.V. Luxembourg Branch, and Quintet Luxembourg.
“The number of funds domiciled in Luxembourg surpasses all other European markets, so the ability to provide depositary services for alternative assets allows CSC to give clients greater flexibility whether they are based here or somewhere else,” said Mifsud.
Cheret, meanwhile, has held senior positions in the alternative investment fund industry in Luxembourg for companies such as Alter Domus, Arendt Services, and Ocorian. He is fluent in five languages and is a qualified chartered accountant.
“I look forward to working with Laurent and Pierre and the rest of our talented, multilingual team in Luxembourg to help our clients navigate the increasingly complex environment they face,” said Cheret. “Whether they need fund administration or depositary services or both, CSC’s centralized team offers clients global reach and unrivaled service quality that is committed to supporting their business.”
About CSC
CSC is a leading provider of specialized administration services to alternative asset managers across a range of fund strategies, capital markets participants in both public and private markets, and corporations requiring fiduciary and governance support. We are the unwavering partner for 90% of the Fortune 500®, nearly 10,000 law firms, and more than 3,000 financial institutions. CSC’s Global Financial Markets professionals are located in key financial centers across the U.S., Europe, and Asia-Pacific. We are a global company capable of conducting transactions wherever our clients are―and we accomplish that by deploying experts in every business we serve. For more information about CSC’s services, visit cscgfm.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005284/en/
Contact information
Jeff Lyons
Public Relations Manager
(302) 636-5401 x65519
jeff.lyons@cscglobal.com
CSC News Room
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
